← Back to Search

Procedure

Deep Brain Stimulation for Movement Disorders

N/A
Recruiting
Led By Kareem A Zaghloul, M.D.
Research Sponsored by National Institute of Neurological Disorders and Stroke (NINDS)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be 18 years of age or older.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Summary

This trial is studying how deep brain stimulation surgery affects people with movement disorders.

Who is the study for?
This trial is for adults over 18 with movement disorders like Parkinson's disease, essential tremor, and dystonia that aren't well-managed by medication. Candidates must be able to understand and agree to the study's procedures.Check my eligibility
What is being tested?
The trial studies Deep Brain Stimulation (DBS) surgery effects on movement disorders. It involves implanting a device to stimulate brain areas linked to movement and recording nerve cell function during surgery.See study design
What are the potential side effects?
Potential side effects of DBS may include headache, infection at the site of surgery or stimulator, speech problems, balance issues, numbness or tingling sensations, and unwanted mood changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
physiology and efficacy of DBS surgery for movement disorders

Side effects data

From 2018 Phase 2 trial • 53 Patients • NCT01221948
23%
Fall
15%
Depression
8%
Hand fracture
8%
Restless legs syndrome
8%
Apathy
5%
Head injury
5%
Dyspepsia
5%
Back pain
5%
Speech disorder
5%
Skeletal injury
5%
Tremor
5%
Gait disturbance
5%
Dystonia
5%
Paraesthesia
5%
Influenza
5%
Urinary tract infection
3%
Akinesia
3%
Parkinson's disease
3%
Syncope
3%
Device migration
3%
Hypoaesthesia
3%
Respiratory depression
3%
Postoperative wound infection
3%
Intervertebral disc protrusion
3%
Pain in extremity
3%
Spinal osteoarthritis
3%
Osteoarthritis
3%
Macular degeneration
3%
Productive cough
3%
Diabetes mellitus
3%
Ingrowing nail
3%
Fluid retention
3%
Diplopia
3%
Skin laceration
3%
Joint sprain
3%
Rib fracture
3%
Drug withdrawal syndrome
3%
Alcohol poisoning
3%
Contusion
3%
Cerebral microangiopathy
3%
Dysarthria
3%
Memory impairment
3%
Movement disorder
3%
Monarthritis
3%
Neck pain
3%
Adverse drug reaction
3%
Cyst
3%
Implant site haematoma
3%
Oedema peripheral
3%
Pyrexia
3%
Pleural effusion
3%
Nerve root lesion
3%
Anxiety
3%
Cough
3%
Fibula fracture
3%
Thermal burn
3%
Sciatica
3%
Anger
3%
Bursitis
3%
Cystitis
3%
Helicobacter gastritis
3%
Implant site infection
3%
Localised infection
3%
Pneumonia
3%
Staphylococcal infection
3%
Confusional state
3%
Depressed mood
3%
Hallucination, auditory
3%
Impulse-control disorder
3%
Insomnia
3%
Panic attack
3%
Rapid eye movements sleep abnormal
3%
Bronchitis
3%
Ear infection
3%
Incision site infection
3%
Arthralgia
3%
Axillary pain
3%
Folate deficiency
3%
Hypertension
3%
Hypotension
3%
Thrombophlebitis
3%
Laboratory test abnormal
3%
Weight increased
3%
Pericardial effusion
3%
Seborrhoeic keratosis
3%
Urinary incontinence
100%
80%
60%
40%
20%
0%
Study treatment Arm
Deep Brain Stimulation

Trial Design

1Treatment groups
Experimental Treatment
Group I: treatment armExperimental Treatment1 Intervention
patients with Parkinson's Disease, dysonia, and essential tremor
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deep Brain Stimulation
2011
Completed Phase 2
~710

Find a Location

Who is running the clinical trial?

National Institute of Neurological Disorders and Stroke (NINDS)Lead Sponsor
1,349 Previous Clinical Trials
647,977 Total Patients Enrolled
Kareem A Zaghloul, M.D.Principal InvestigatorNational Institute of Neurological Disorders and Stroke (NINDS)
7 Previous Clinical Trials
631 Total Patients Enrolled

Media Library

Deep Brain Stimulation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT01581580 — N/A
Parkinson's Disease Research Study Groups: treatment arm
Parkinson's Disease Clinical Trial 2023: Deep Brain Stimulation Highlights & Side Effects. Trial Name: NCT01581580 — N/A
Deep Brain Stimulation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01581580 — N/A
~58 spots leftby Dec 2029